OncoAlert 4Sight Abstracts to be Presented at #ESMO26
First-Line Pembrolizumab + Lenvatinib + Belzutifan or MK-1308A + Lenvatinib in Advanced RCC: The Randomized Open-Label Phase 3 LITESPARK-012 Study

@DrChoueiri
@tompowles1
@MVossMD
@ERPlimackMD
@HowardGurney
@brian_rini

🔬 Phase 3 (n=1688), untreated advanced ccRCC: pembrolizumab + lenvatinib + belzutifan (Arm A) or MK-1308A + lenvatinib (Arm B) vs pembrolizumab + lenvatinib. Dual primary: PFS by BICR and OS.

➡️ Arm A: PFS HR 1.08 (0.93–1.26); OS HR 1.04 (0.87–1.25)
➡️ Arm B: PFS HR 1.07 (0.92–1.25); OS HR 1.12 (0.94–1.35)
➡️ Discontinuation due to AEs: 51.6% (A), 51.4% (B), 36.2% (control)
✅ Neither belzutifan nor CTLA-4 blockade added to pembrolizumab + lenvatinib improved efficacy; pembrolizumab + lenvatinib remains a 1L SOC. #KidneyCancer

🎙️ Toni Choueiri
👥 Thomas Powles · Martin Voss · Elizabeth Plimack · Howard Gurney · Yue Song · Rodolfo Perini · Karla Rodriguez-Lopez · Brian Rini

(4Sight Made solely from Abstracts publicly available at the ESMO website)
Pinging Our Faculty
@tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper